HOME >> MEDICINE >> NEWS
Twice daily imatinib could improve outcome for people with specific form of gastro-intestinal cancer

This release is also available in German.

Results of a randomised trial in this week's issue of THE LANCET suggest that a single daily 400 mg dose of imatinib--known to be a first-choice treatment for gastro-intestinal stromal tumours (GIST)--is sufficient to induce a therapeutic response; a doubling of a daily dose can slightly improve progression-free survival for patients.

Imatinib is approved worldwide for use in GIST, tumours which do not respond to conventional chemotherapy, which have a prevalence of around 20 per 100,000 population. Jaap Verweij (Erasmus University Medical Center, Netherlands) and colleagues from the European Organisation for Research and Treatment of Cancer (EORTC), the Italian Sarcoma Group (IRG), and the australasian Gastrointestinal Trials Group (AGITG) studied 946 patients with metastatic GIST who were randomly allocated either imatinib 400 mg once or twice a day.

50% of patients receiving two doses of imatinib a day, compared with 56% of patients given a single dose, were alive and free of disease progression at around 2 years follow-up. There was no difference in the proportion of patients (99%) who reported treatment side-effects; the optimum time for therapeutic effect after the start of treatment did not differ between the two groups (around 4 months).

Dr Verweij comments: "If the aim of treatment is response induction, a daily dose of 400 mg given for 46 months seems to be sufficient. However, in patients with widespread metastatic disease, the prolonged progression-free survival achieved with 400 mg twice daily might lead one to favour this regimen. Whether a similar outcome could be achieved with fewer side-effects by making use of the reduction in drug clearance over time--eg, with a starting dose of 400 mg daily followed by stepwise dose escalation to 400 mg twice a day--is still a matter for further clini
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
23-Sep-2004


Page: 1 2

Related medicine news :

1. Study: Among Heart Failure Patients, Women Survive Twice As Long As Men
2. Bullying among sixth graders a daily occurrence, UCLA study finds
3. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
4. African children with HIV would benefit from daily doses of cheap antibiotic
5. Weekend use matches daily drops for lazy eye
6. New ways identified to treat lazy eye in children: Beyond eye patches and daily drops
7. Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment
8. Study finds once-daily Valcyte prevents serious viral infection after kidney transplant
9. Max daily OTC dose of acetaminophen shows efficacy comparable to Rx doses of naproxen for OA pain
10. New study finds even a small amount of psoriasis can negatively impact daily life
11. OHSU study shows four daily servings of fruits & vegetables reduce breast cancer risk by half

Post Your Comments:
(Date:3/31/2015)... (PRWEB) March 31, 2015 As the ... Fitness is pledging to have a mobile-friendly website online ... is part of Chunk Fitness’ continued commitment to bring ... growing user base. All of the same great fitness ... it will be substantially easier to read while browsing ...
(Date:3/31/2015)... CA (PRWEB) March 31, 2015 Cosmetic ... on the Internet, is proudly enduring adding news to ... doctors and the consumers of plastic surgery and cosmetic ... more user-friendly pages and interconnected sections, the Cosmetic Town ... newest addition to the Cosmetic Town site navigation, News ...
(Date:3/31/2015)... 31, 2015 In conjunction with ... April 1-7, the Mesothelioma Applied Research Foundation (Meso ... program, to complement its existing work in mesothelioma ... part of the Meso Foundation’s mission, we want ... diseases related to asbestos, including mesothelioma,” said the ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 In ... (ADS) is offering advice for buying from a ... Dealers Association (NMEDA) is a nonprofit organization that ... in the manufacturing and installation of mobility equipment. ... in the industry that consistently adhere to the ...
(Date:3/31/2015)... March 31, 2015 Calling all runners, walkers ... and other tick-borne diseases! The first annual “Lyme Walk & ... Park in Stamford, CT. The event, hosted by Lyme ... will raise funds to support research and education about Lyme ... to all ages and abilities, will feature 5K and 10K ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:Advanced Driving Systems Celebrates National Disability Month 2Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2
(Date:3/31/2015)...  Dr. Renu Razdan of leading Indian CRO ... Congress in April to discuss the latest, progressive announcement regarding ... drugs below: India,s Drugs ... Health that if a new drug is approved and marketed ... India with waiver of clinical trial ...
(Date:3/31/2015)... ALPHARETTA, Ga. , March 31, 2015   ... Health Care, today announced it was awarded a new ... line of face masks. Effective March 1, 2015, Halyard,s ... masks with SO SOFT* lining, will be available to ... as well as 15,000 ambulatory surgery centers, physician practices ...
(Date:3/31/2015)... NEW YORK , March 31, 2015 ... ) announced today that it intends to expand its ... fully human monoclonal antibody targeting eotaxin-1. Bullous Pemphigoid is ... approximately 60,000 patients in the US and ... expects to start enrolling patients in a Phase II ...
Breaking Medicine Technology:Max Neeman to Discuss India's Orphan Drug Regulations at WOD 2015 2Halyard Health Signs First GPO Contracts As Independent Company 2Halyard Health Signs First GPO Contracts As Independent Company 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 4
Cached News: